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Endogenousmechanisms for successful resolution of an acute inﬂammatory response and
the local return to homeostasis are of interest because excessive inﬂammation underlies
many human diseases. In this review, we provide an update and overview of functional
metabolomics that identiﬁed a new bioactive metabolome of docosahexaenoic acid (DHA).
Systematic studies revealed that DHA was converted to DHEA-derived novel bioactive
products as well as aspirin-triggered forms of protectins (AT-PD1). The new oxygenated
DHEA-derived products blocked PMN chemotaxis, reduced P-selectin expression and
platelet-leukocyte adhesion, and showed organ protection in ischemia/reperfusion injury.
These products activated cannabinoid receptor (CB2 receptor) and not CB1 receptors. The
AT-PD1 reduced neutrophil (PMN) recruitment in murine peritonitis. With human cells,
AT-PD1 decreased transendothelial PMN migration as well as enhanced efferocytosis
of apoptotic human PMN by macrophages. The recent ﬁndings reviewed here indicate
that DHEA oxidative metabolism and aspirin-triggered conversion of DHA produce potent
novel molecules with anti-inﬂammatory and organ-protective properties, opening the DHA
metabolome functional roles.
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THE NEUTROPHIL (PMN) IN RESOLUTION AND THE
PROGRAMMED OUTCOME OF ACUTE INFLAMMATION
The acute inﬂammatory response has several potential outcomes
that include progression to chronic inﬂammation, scarring, and
ﬁbrosis or ideally complete resolution, see Kumar et al. (2005).
Acute inﬂammation is a response that eliminates or neutralizes
foreign bodies or organisms and is protective against injury or
infection (Kumar et al., 2005; Serhan et al., 2010). This process
is characterized by vascular dilation, enhanced permeability of
capillaries, increased blood ﬂow, and the production of ﬁbrin-
rich exudates (Majno and Joris, 2004). Vascular permeability and
increased blood ﬂow permit leukocyte recruitment from the cir-
culation postcapillary venules (Figure 1) to form the PMN-rich
exudate (Ryan and Majno, 1977). Leukocyte recruitment is clas-
sically deﬁned by the initial trafﬁcking of polymorphonuclear
(PMN) granulocytes followed by monocytes that differentiate
locally intomacrophages (Figure 1). These events in pro-resolving
responses are coupled with release of factors that prevent further
or excessive trafﬁcking of leukocytes in self-limited inﬂamma-
tion allowing for resolution (Serhan et al., 2000, 2002; Serhan and
Savill, 2005). Pro-inﬂammatory mediators such as prostaglandins
and leukotrienes play an important role (Borgeat and Samuels-
son, 1979; Samuelsson, 1983; Samuelsson et al., 1987) early in the
response, stimulating vascular changes as well as PMN recruit-
ment. These events involve LTB4 and IL-8, potent PMN chemoat-
tractants, as well as many other endogenous and exogenous
chemoattractants.
Theprogression fromacute to chronic inﬂammation as inmany
widely occurring human diseases such as arthritis, periodontal
disease, and cardiovascular disease, is generally viewed as an excess
of pro-inﬂammatory mediators, but may also arise via a failure
in mechanisms to resolve (Serhan, 2011). Although mononu-
clear cells can in many settings contribute to pro-inﬂammatory
responses, they are also critical in wound healing, tissue repair,
and remodeling in a non-inﬂammatory, non-phlogistic manner
(Stables et al., 2011; Ariel and Serhan, 2012). Most successful
inﬂammatory processes are self-limiting (Majno and Joris, 2004),
which implies the existence of endogenous anti-inﬂammation
pathways (Serhan et al., 2004; Serhan and Savill, 2005).
Complete or successful resolution of an acute inﬂammatory
response and the local return to homeostasis is necessary for ongo-
ing health. The ideal outcome is the removal of leukocytes from
infected or inﬂamed tissues without leaving remnants of the host’s
combat between leukocytes, invading microbes, and/or other ini-
tiators of inﬂammation. The authors’ research efforts have focused
on identiﬁcation of mediators involved in the successful resolu-
tion process (Serhan, 2007). It was widely believed and argued
that simple dilution of pro-inﬂammatory mediators was enough
to “turn off” or “burn out” inﬂammation, with the subsequent
responses ending naturally or passively (Kumar et al., 2005). Now,
a body of evidence indicates that resolution of acute inﬂamma-
tion and the return to homeostasis is not simply passive, but an
active and highly regulated process that can be considered pro-
grammed resolution at the tissue level (Serhan, 2007;Morris et al.,
2010). In this regard, the specialized pro-resolving lipid media-
tors (SPMs) comprise a genus (chemically distinct families) of
endogenous mediators, including lipoxins, resolvins, protectins,
and maresins (Serhan et al., 2009; Figure 2; Table 1). They
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FIGURE 1 |The role of chemical mediators in the acute inflammatory
response. At the site of tissue injury or bacterial invasion, both exogenous
and endogenous chemical mediators are liberated. Classic endogenous
mediators such as prostaglandins and leukotrienes dilate vasculatures,
enhance permeability of capillaries, increase blood ﬂow, and stimulate the
recruitment of neutrophils (PMNs) to form inﬂammatory exudate. Novel
chemical mediators are produced in the evolution and resolution of the
exudate that regulate tissue responses (see text for details). The black arrow
denotes leukocyte trafﬁc from venules and the dashed arrow denotes
exogenous, i.e., bacterial components and chemoattractants.
FIGURE 2 |The fate of DHA in its new metabolome in vivo. Via
esteriﬁcation, DHA enters phospholipids and triglycerides that can circulate or
reside in cell membranes. Autooxidation of DHA can produce
neuroisoprostanes, the DHA form of isoprostanes. Enzymatic conversion in
local inﬂammatory exudates can generate the specialized pro-resolving lipid
mediators (SPMs), including D-series resolvins, protectins, and maresins.
are actively biosynthesized during the resolution phase of acute
inﬂammation and are potent agonists that control the magnitude
and duration of inﬂammation. During resolution of inﬂamma-
tion, ω-3 fatty acids are rapidly imported (Kasuga et al., 2008) to
the resolving exudate from circulation along with albumin and
trafﬁcking leukocytes that are then used as substrates to pro-
duce the local-acting E-series resolvins (Oh et al., 2011), D-series
resolvins and protectins as well as maresins (Serhan et al., 2009).
Each of these new families of potent local mediators carries both
anti-inﬂammatory as well as pro-resolving actions in that they
stop PMN (limit their further inﬂux) to the site of inﬂammation
and stimulate efferocytosis (Spite and Serhan, 2010; Serhan, 2011).
Docosahexaenoic acid (DHA) is unique in this regard because it
has several fates in its metabolome (Figure 2). DHA undergoes
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Table 1 | Key structures of the SPM: resolvins, protectins, and maresins
RvE1 Resolvin E1 (5S,12R,18R-trihydroxy-eicosa-6Z,8E,10E,
14Z,16E -pentaenoic acid)
RvE2 Resolvin E2 (5S,18R-dihydroxy-eicosapentaenoic acid)
PD1/NPD1 Protectin D1/neuroprotectin D1 (10R,17S-dihydroxy-docosa-
4Z,7Z,11E,13E,15Z,19Z -hexaenoic acid)
RvD1 Resolvin D1 (7S,8R,17S-trihydroxy-4Z,9E,11E,13Z,15E,19Z -
docosahexaenoic acid)
RvD2 Resolvin D2 (7S,16R,17S-trihydroxydocosa-4Z,8E,10Z,12E,
14E,19Z -hexaenoic acid)
RvD3 Resolvin D3 (4S,11,17S-trihydroxydocosa-5,7E,9E,13Z,
15E,19Z -hexaenoic acid)
RvD4 Resolvin D4 (4S,5,17S-trihydroxydocosa-6E,8E,10Z,
13Z,15E,19Z -hexaenoic acid)
RvD5 Resolvin D5 (7S,17S-dihydroxy-docosa-4Z,8E,10Z,13Z,
15E,19Z -hexaenoic acid)
MaR1 Maresin 1 (7,14-dihydroxy-docosa-4Z,8,10,12,16Z,19Z -
hexaenoic acid)
Complete structures of the key SPM are reported and total organic synthesis was
recently reviewed in Serhan and Petasis (2011).
esteriﬁcation to form complex lipids that circulate or reside in
phospholipid membranes of cells and tissues (Bazan et al., 2010),
or can undergo autooxidation of the products such as neuroiso-
prostanes that are potentially pro-inﬂammatory (Roberts et al.,
1998; Roberts and Morrow, 2002), or undergo conversion in
inﬂammatory exudates to potent pro-resolving mediators such
as the SPMs. Hence, the fate of DHA is governed, in part, locally
in its microenvironment and hence “when and where” determines
its action and impact in vivo (Figures 2 and 3) in addition to DHA
as a precursor to resolvins and their aspirin-triggered (AT) forms
(Serhan et al., 2002). Systematic studies reveal that DHA is con-
verted to DHEA-derived novel products (Yang et al., 2011) as well
as AT forms of protectins (Serhan et al., 2011; see Figure 3). These
are the main subjects of this review and are detailed in the next
sections.
FUNCTIONAL METABOLOMICS AND THE NEW DHA
METABOLOME
LC–UV–MS–MS IDENTIFICATION OF 17-HDHEA
To investigate the potential endogenous generation of DHEA-
derived bioactive products in mice, brain was harvested and
subject to solid phase extraction (Yang et al., 2011). Next, the
methyl formate fractions were taken for LC–UV–MS–MS-based
metabolomics. Tandemmass fragmentations and online UV spec-
trum with characteristic λmax at 237 nm were consistent with the
structure as shown in Figure 4 and Yang et al. (2011). Because
of the lack of suitable functional groups for direct efﬁcient ion-
ization and analysis of 17-hydroxy-4Z, 7Z, 10Z, 13Z, 15Z, 19Z -
docosahexaenoylethanolamide (17-HDHEA) for LC–MS–MS, its
acetate adduct m/z 446= [M+CH3COOH-H] was targeted. The
major tandem mass ions were assigned for: m/z 386= [M−H],
368= [M−H – H2O], 281= [299 – H2O]. The m/z 288 is consis-
tent with fragmentation at position 17 (Figure 4 and Yang et al.,
2011).
Because of the limited quantities of endogenous 17-HDHEA
produced in brain tissue, further studies and in vitro enzymatic
preparation were carried out by incubating DHEA with 15-LOX
followed by reduction with NaBH4. Endogenous 17-HDHEA and
the enzymatically prepared compound in vitro gave essentially
the same LC retention times and tandem mass fragmentations.
To assess their production by human and mouse tissues, DHEA
was also incubated with isolated human PMN or whole mouse
brain because DHEA is enriched in this tissue. LC–MS–MS-based
targeted lipidomics indicated the production of a novel series of
oxygenated products (see Figure 4).
DECODING
As second approach in parallel to structure elucidation, screen-
ing of HPLC-isolated DHEA metabolites obtained from mouse
brain was carried out utilizing a microﬂuidic chamber (Irimia
et al., 2006; Kasuga et al., 2008). After a gradient of IL-8 was
introduced to the main channel of the device, P-selectin tethered
leukocytes rapidly migrated in the IL-8 gradient at an average
rate of 2.3μm/min. Next, a mixture of isolated metabolites was
infused into the main channel. Human PMN chemotaxis is dra-
matically reduced upon the addition of the brain metabolite mix-
ture. For example, the average human PMN chemotaxis velocity
dropped from 2.3 to ∼ 0.7μm/min (Yang et al., 2011). These
results indicated that the brain fraction of metabolites contained
products that stopped PMN chemotaxis. Results from this screen-
ing uncovered that at least one bioactive product was present
among the mixture of DHEA metabolites. Hence, we next pur-
sued the metabolic fates of DHEA and 17-HpDHEA/17-HDHEA
identiﬁed inmouse brain (Yang et al., 2011) using LC/UV/MS/MS-
based lipidomics.Aswith 17-HDHEA, acetate adducts of potential
DHEA-derived novel metabolites [M+CH3COOH-H] were tar-
geted for tandem mass analysis. From these studies we identiﬁed
the presence and production of novel products in the DHEA
metabolome (Figure 4).
Human PMN incubated with either DHEA or 17-HpDHEA
led to the generation of 17-HDHEA, 4,17-diHDHEA, 10,17-
diHDHEA, and 15-HEDPEA (see Figure 4 and Yang et al., 2011).
Human hemoglobin, which can be liberated upon tissue dam-
age (Kumar et al., 2005), was next incubated with 17-HpDHEA.
This gave 13-HEDPEA and 15-HEDPEA as prominent products,
as well as 17-HDHEA (see Figure 4). Mouse brain homogenates
with DHEA also produced 17-HDHEA and 4,17-diHDHEA
as major products with smaller amounts of 7,17-diHDHEA,
10,17-diHDHEA, and 15-HEDPEA. The adduct parent ion, ana-
lyte parent ion and the ions resulted from neutral loss are
m/z 462= [M+CH3COOH-H], 402= [M−H], 384= [M−H –
H2O], 366= [M−H – 2H2O], which are common signature ions
for all dihydroxy-containing DHEA products. The ions m/z 333,
315= [333 – H2O], 304, 286= [304-H2O] were assigned as diag-
nostic ions for fragmentations at position 17. Fragmentations at
position 4 can lead to m/z 144, 257 and 239= [257-H2O]. Its
UV spectrum displayed characteristic maximum absorbance at
238 nm, which was consistent with the presence of two separated
conjugated diene structures in this compound. Diagnostic ions
m/z 304, 286= [304-H2O], 184, 156, corresponded to the frag-
mentations at positions 7 and 17 of 7,17-diHDHEA respectively
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FIGURE 3 | DHA bioactive metabolome. DHA is the precursor to D-series
resolvin (RvD), aspirin-triggered resolvin D (AT-RvD), maresins (MaR), protectin
D1 (PD1), and aspirin-triggered protectin D1 (AT-PD1). Another metabolic fate
of DHA is conversion to docosahexaenoyl ethanolamide (DHEA). See text for
details on the recently identiﬁed novel series of bioactive oxygenated
DHEA-derived products including 15-HEDPEA and 10,17S-diHDHEA.
(Yang et al., 2011). The UV spectrum of the compound displayed
maximum absorbance, λmax, at 246 nm (Tjonahen et al., 2006),
consistent with the presence of two diene structures separated by
a methylene group. For 10,17-diHDHEA, m/z 333, 315= [333-
H2O], 304, 286= [304-H2O], 196 came from fragmentations at
positions 10 and 17 (Yang et al., 2011). The presence of a con-
jugated triene structure in 10,17-diHDHEA was conﬁrmed by
the characteristic UV spectrum with λmax at 270 nm. Tandem
mass spectrum of 13-HEDPEA (Yang et al., 2011) gave signa-
ture fragmentation ions m/z 320, 304, 286= [304-H2O], 236.
GC/MS was also utilized for additional structural analysis with
13-HEDPEA and 15-HEDPEA that helped to conﬁrm the tandem
MS assignments.
To determine concentrations, as well as to further conﬁrm
structures, HPLC-isolated 13-HEDPEA and 15-HEDPEA were
characterized using proton NMR (1HNMR). In the chemical shift
assignments (Yang et al., 2011) for 15-HEDPEA, the proton at posi-
tion 15 (H-15) displayed two distinct chemical shifts. Because of
limited amounts of materials and the lack of informativeUV chro-
mophores present in these compounds, NMR spectroscopy was
also used for quantitation using 17-HDHA as an internal standard
with known concentrations. Each NMR quantitated compound
was then used for HPLC calibration and quantitation (Yang et al.,
2011).
Each of these HPLC-isolated dioxygenated DHEA products
were screened for direct PMN actions using microﬂuidic cham-
bers and freshly isolated PMN (Yang et al., 2011). Infusion of
isolated 15-HEDPEA at 10 nM to the main channel stimulated
changes in morphology and chemotaxis of human PMN in the
IL-8 gradient and stopped further PMN migration (Figure 4).
For direct comparison, PMN chemotaxis velocity did not change
with time with the IL-8 gradient. Also, at 10 nM, 4,17-diHDHEA,
7,17-diHDHEA, or 10,17-diHDHEA did not signiﬁcantly regulate
chemotaxis, whereas at higher concentrations, e.g., 10μM, 10,17-
diHDHEA rapidly stopped PMN. Together, these results indicated
that 15-HEDPEA is the most potent of this series in regulating
human PMN shape change and motility.
CANNABINOID RECEPTORS AND NOVEL DHEA PRODUCTS
Because AEA exerts a wide range of bioactions via activat-
ing cannabinoid receptor(s) (Devane et al., 1992; Felder et al.,
1993), we therefore tested whether DHEA, 10,17-diHDHEA or
15-HEDPEA also activated CB receptors. For these experiments,
we used recombinant human CB receptors over-expressed in a
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FIGURE 4 | Novel pathways and oxygenation products from DHEA. DHEA
is ﬁrst converted to 17-HpDHEA by 15-LOX. Next, 17-HpDHEA is partially
reduced to the oxide radical, which reacts with the vicinal double bond at the
16-position to yield the 16(17)-epoxide radical (see text andYang et al., 2011).
Non- or low stereospeciﬁc addition of oxygen to the intermediate leads to
formation of two types of peroxide radical diastereomers; their further
reduction produces 13-HEDPEA and 15-HEDPEA. Via a LOX-related
mechanism, 17-HpDHEA is converted to 10, 17S-diHDHEA or directly reduced
to 17S-HDHEA. 10, 17S-diHDHEA, and 15-HEDPEA block PMN chemotaxis,
reduce P-selectin expression and aggregation of platelets and leukocytes, and
show organ protection in ischemia/reperfusion injury. Although these new
products directly act on recombinant CB2 receptors in vitro, the activation of
CB2 in vivo and/or additional receptors in vivo by 10,17S-diHDHEA and
15-HEDPEA remains of interest.
www.frontiersin.org April 2012 | Volume 3 | Article 81 | 5
Shinohara et al. Functional metabolomics
beta-arrestin system. HPLC puriﬁed AEA was used for direct
comparison as a known receptor agonist of CB1 (Janero and
Makriyannis, 2007; Vemuri et al., 2008). In these experiments,
activation of CB2 by AEA gave EC50 ∼ 1.1× 1010 M and DHEA
9.8× 10−9 M. For comparison, EC50 formetabolically oxygenated
products, 10,17-diHDHEA and 15-HEDPEA, were 3.9× 10−10
M and 1.0× 10−10 M (Yang et al., 2011). These results demon-
strated that the novel enzymatic oxidation products from DHEA
are activators of CB2 receptors, and that 10,17-diHDHEA and 15-
HEDPEA also activated CB1 receptors but required much higher
concentrations. In this system, 15(S)-HETE ethanolamide (oxy-
genated product of AEA) did not stimulate CB2 receptors in this
dose range. CB2 receptor-ligand interactions were conﬁrmed with
dose response of CB2 speciﬁc antagonist AM630.When incubated
with GPCR CB2 over-expressed cells, AM630 inhibited activation
stimulated with 15-HEDPEA (10 nM) and AEA (10 nM). AM630
also inhibited GPCR CB2 interaction with 10,17-diHDHEA at
higher concentration (Yang et al., 2011).
NOVEL DHEA PRODUCTS REDUCED PLATELET-LEUKOCYTE
AGGREGATE
Platelet-leukocyte interactions play important roles in hemosta-
sis, thrombosis, and inﬂammation (for a recent review see van
Gils et al., 2009 and references within). At concentrations as
low as 10 pM, 10,17S-diHDHEA or 15-HEDPEA decreased PAF-
(100 nM) stimulated platelet-monocyte aggregate formation in
human whole blood by ∼30% (Yang et al., 2011). The inhibitory
action of 10,17-diHDHEA displayed a bell-shaped dose response
and reached maximum reduction at∼40% with 100 pM. The for-
mation of PMN-platelet aggregates with PAF (100 nM) was also
inhibited by 10,17-diHDEA at concentrations as low as 10 pM,
as was the surface expression of P-selectin on platelets in human
whole blood (Figure 4). By comparison, the precursor DHEA was
not active in this dose range.
NOVEL DHEA PRODUCTS ARE ORGAN PROTECTIVE IN
ISCHEMIA/REPERFUSION INJURY
15-HEDPEA displayed potent bioactions with human PMN at
single-cell level (Figure 4 and Yang et al., 2011) and in human
whole blood; hence, we questioned whether it had protective
actions in vivo in murine hind limb ischemia (1 h) and second
organ reperfusion (2 h) injury (Qiu et al., 2000). Indeed, fol-
lowing reperfusion, 15-HEDPEA signiﬁcantly reduced lung PMN
accumulation in mice and associated lung injury at 1μg/mouse
(Figure 4 andYang et al., 2011;∼50% reduction directly compared
with vehicle).
Lipidomic investigation of DHEA functional metabolome
uncovered a series of novel oxygenated products that (1) are potent
CB2 agonists, (2) regulate single-cell PMN chemotactic responses,
(3) modulate platelet-leukocyte interaction in whole blood, and
(4) are organ protective. In view of the role of lipid mediators in
inﬂammation and its resolution as well as homeostasis (Serhan
et al., 2008), the present new DHEA metabolome documented
herein may serve as a counter-regulatory system in neural tissues
and those rich in DHEA as well as in administration of DHA
(Calder, 2010) to regulate leukocyte-mediated tissue damage. The
link betweenCB2 receptor activation in vitro and in vivo actions of
these novel products remains to be established. Also, it is possible
that additional receptors in vivo may be functionally regulated by
these new DHEA products.
ASPIRIN AND DHA: UNCOVERING THE AT-(NPD1/PD1)
PATHWAY
Aspirin is well appreciated for its ability to inhibit COX-1 and
inactivate this enzyme. On the other hand, the catalytic region of
COX-2 is larger than that of COX-1, and when it is acetylated by
aspirin, acetylatedCOX-2 remains active, producing lipoxygenase-
like products, demonstrated in vivo in humans (Chiang et al., 2004;
Chiang and Serhan, 2004). Aspirin is unique in that it can jump-
start resolution by triggering production of E-series and D-series
resolvins and AT-lipoxins (Serhan et al., 2000, 2002; Schwab et al.,
2007; Morris et al., 2009). The previously unrecognized mediators
and mechanisms involve the biosynthesis of AT lipid mediators.
With Dr. Bazan (LSU) and Dr. Petasis (USC), we established DHA
conversion to the AT-NPD1 pathway (Serhan et al., 2011).
To determine the complete stereochemical assignment and
bioactions of AT-(NPD1/PD1), we directly compared the phys-
ical and biological properties of DHA-derived AT-(NPD1/PD1)
and related 10,17 dihydroxy-docosatriene stereoisomers produced
by leukocytes to those prepared in stereochemically pure form by
total organic synthesis (Serhan et al., 2011). SinceAT-(NPD1/PD1)
was identiﬁed in resolving murine exudates treated with aspirin
(Serhan et al., 2002), biologic AT-(NPD1/PD1) was obtained from
resolving murine exudates in vivo. To this end, peritonitis was
initiated via intra-peritoneal (i.p.) administration of zymosan A
(1mg/mouse), and exudates were harvested 24 h post injection
(i.e., within the resolution phase; Bannenberg et al., 2005). Exu-
dateswere subject to solid phase extraction and analyzedusingLC–
UV–MS–MS-based mediator lipidomics. AT-(NPD1/PD1) was
also isolated and identiﬁed from activated human leukocytes,
namely, aspirin-treated human PMN. Collectively, by matching
biologic materials from both human and murine exudate AT-
(NPD1/PD1) with synthetic candidates, these results established
the complete stereochemistry of endogenous AT-(NPD1/PD1) as
10R,17R-dihydroxydocosa-4Z, 7Z, 11E, 13E, 15Z, 19Z -hexaenoic
acid (Serhan et al., 2011).
ANTI-INFLAMMATORY ACTIONS OF AT-NPD1/PD1
Earlier results indicated that NPD1/PD1 exerted potent anti-
inﬂammatory actions regulating leukocyte trafﬁcking in murine
systems (Serhan et al., 2002; Hong et al., 2003). We compared
the bioactions of NPD1/PD1 to those of AT-(NPD1/PD1) carried
out in parallel with the physical matching experiments (Serhan
et al., 2011). Synthetic AT-(NPD1/PD1) limited PMN inﬁltration
into the peritoneum in TNFα-stimulated peritonitis (Figure 5).
Both NPD1/PD1 (0.1–10 ng) and AT-(NPD1/PD1; 0.01–10.0 ng)
proved to be signiﬁcant regulators of TNFα-stimulated leuko-
cyte inﬁltration into the peritoneum. AT-(NPD1/PD1) reduced
total leukocyte population of the exudate including PMN, mono-
cyte and lymphocyte inﬁltrates, reaching a maximal reduction at
1 ng/mouse by as much as 50.4± 8.8%. The PMN population
was also reduced with AT-(NPD1/PD1) reaching a maximal PMN
reduction at 1 ng/mouse (62.2± 7.8%; Serhan et al., 2011). The
ﬂow cytometry results obtained with murine exudates indicated
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FIGURE 5 | Proposed biosynthesis scheme for protectin D1 (PD1) and
aspirin-triggered protectin D1 (AT-PD1). DHA is ﬁrst converted to
17S-HpDHA intermediate by 15-LOX. Then PD1 is generated through 16S,
17S-epoxide. In the aspirin-triggered pathway, 17R-HpDHA is generated from
DHA via acetylated-COX, and converted to AT-PD1 via a 16R, 17R-containing
epoxide intermediate. Both PD1 and AT-PD1 reduce leukocytes and PMN
inﬁltration in peritonitis stimulated by either TNF-α or zymosan A. PD1 and
AT-PD1 each enhance human macrophage efferocytosis of apoptotic human
PMNs and limit human PMN transmigration across human endothelial cells,
the deﬁning pro-resolving bioactions.
a reduction in the Ly6G+CD11b+ population as compared to
TNFα alone. Of note, the Δ15-trans-AT-(NPD1/PD1) isomer
did not reduce either the total exudate leukocyte population or
PMN inﬁltration. Since NPD1/PD1 limited PMN inﬁltration in
zymosan A-initiated peritonitis (Serhan et al., 2006), we deter-
mined whether AT-(NPD1/PD1) also reduced PMN inﬁltration in
zymosan A-stimulated peritonitis. AT-(NPD1/PD1; 0.1–100.0 ng)
signiﬁcantly reduced total leukocytes, as well as PMN inﬁltration,
reaching a maximal reduction of 47.8± 10.0% and 49.1± 11.9%.
In comparison to AT-(NPD1/PD1; 1.0 and 10.0 ng), equal
doses of either the precursor DHA or Δ15-trans-AT-NPD1/PD1
did not reduce either total leukocyte inﬁltration or PMN
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inﬁltration (Serhan et al., 2011). These ﬁndings indicated that
AT-(NPD1/PD1) regulates inﬂammatory responses inducedby the
pro-inﬂammatory cytokine TNFα and the TLR ligand, zymosanA.
PMN-TRANSENDOTHELIAL MIGRATION AND ENHANCED
EFFEROCYTOSIS
PMN-transendothelial migration is the ﬁrst committed step
of leukocytes in acute inﬂammation (Kumar et al., 2005).
AT-(NPD1/PD1) and NPD1/PD1 (0.1–10.0 nM) reduced (∼30
and ∼50%) PMN-transendothelial migration stimulated by
LTB4. Equal concentrations of the Δ15-trans isomer of AT-
(NPD1/PD1) where the conjugated triene portion of the mol-
ecule was in the trans rather than cis conﬁguration did not
reduce PMN-transendothelial migration. Again, the precursor
DHA (Kasuga et al., 2008) did not reduce LTB4-stimulated PMN-
transendothelial migration (Serhan et al., 2011). To corroborate
these, we also used an electric cell-substrate impedance sensing
system (ECIS) that sensitively quantitates cellular responses in two
cell systems by real-time monitoring of barrier impedance (Tsiki-
tis et al., 2004). Both AT-(NPD1/PD1) and NPD1/PD1 (1nM)
decreased LTB4-stimulated PMN-transendothelial migration, and
AT-(NPD1/PD1) also enhanced the uptake of apoptotic human
PMN by human macrophages at concentrations as low as 0.1 nM,
as did NPD1/PD1 when compared directly. The response was
bell-shaped and consistent with the dose response relationship
observed for efferocytosis and pro-resolving lipid mediators such
as RvE1 (Hong et al., 2008).
SOME CONSIDERATIONS FOR THE FUTURE
In summation, the novel products and pathway metabolome
reviewed here might have protective and anti-inﬂammatory
actions relevant in humans. This important level of evidence is
of interest and remains to be established in human trials. For
example, since RvE1 has a direct protective effect on cardiomy-
ocytes against ischemia-reperfusion injury limiting infarct size
when administered intravenously just before reperfusion (Keyes
et al., 2010), the novel bioactive DHEA products discussed in this
reviewmay carry potential clinical applications. These newDHEA
products (Figure 4) and/or related structures might be useful in
the treatment of acute myocardial infarction, because platelet and
neutrophil interactions have a key regulatory role in the site of
inﬂammation (Marcus et al., 1982; Phillipson and Kubes, 2011).
Along these lines, Pillai et al. (2012) from this laboratory recently
reported on the time course and identiﬁcation of inﬂammatory
mediators (both cytokine and lipid mediators) after abdominal
aortic aneurysm (AAA) surgery. Chemical mediator proﬁles from
patients that had undergone AAA in that study assembled into
two groups. The temporal proﬁles for local chemical mediators
from these patients were either those with a pro-inﬂammatory
proﬁle of localmediators or a second groupwith a potential resolv-
ing proﬁle of local mediators. These recent reports and results
reviewed herein suggest that the temporal biosynthesis of local
chemical mediators following inﬂammation or tissue injury can
have an acute local impact as well as long-term effects following
surgical intervention and tissue remodeling. Hence, knowledge of
these new mediators and pathways as well as their potential roles
may serve as a basis for new and more effective therapeutics that
could improve the outcomeof diseases, surgery and post-operative
events.
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